Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
1998

Intensive Weekly Chemotherapy for Locally Advanced Gastric Cancer

Sample size: 32 publication Evidence: moderate

Author Information

Author(s): S Cascinul, R Labianca, F Graziano, G Pancera, S Barni, L Frontini, G Luporini, R Cellerino, G Catalano

Primary Institution: Italian Group for the Study of Digestive Tract Cancer (GISCAD)

Hypothesis

Can preoperative chemotherapy improve surgical resectability in patients with locally advanced unresectable gastric cancer?

Conclusion

The study found that intensive weekly chemotherapy enabled resection in half of previously inoperable tumors with moderate toxicity.

Supporting Evidence

  • Fifteen of 32 patients (47%) responded to chemotherapy.
  • Thirteen of the responding patients were completely resected after chemotherapy.
  • At a median follow-up of 24 months, 10 of 13 resected patients are alive and eight are relapse-free.
  • Median survival for the whole group was 11 months, with 14 months for resected patients.

Takeaway

Doctors gave special medicine to patients with stomach cancer to help them get better and have surgery. Many patients got better and could have their tumors removed.

Methodology

Patients received a weekly chemotherapy regimen consisting of cisplatin, 5-fluorouracil, epidoxorubicin, leucovorin, glutathione, and filgrastim over eight weeks.

Limitations

The study did not include a formal assessment of symptom control.

Participant Demographics

{"age":{"median":60,"range":"42-71"},"sex":{"male":21,"female":11},"performance_status":{"0":19,"1":9,"2":4}}

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication